ATE438644T1 - Chinazolinderivate - Google Patents

Chinazolinderivate

Info

Publication number
ATE438644T1
ATE438644T1 AT07009390T AT07009390T ATE438644T1 AT E438644 T1 ATE438644 T1 AT E438644T1 AT 07009390 T AT07009390 T AT 07009390T AT 07009390 T AT07009390 T AT 07009390T AT E438644 T1 ATE438644 T1 AT E438644T1
Authority
AT
Austria
Prior art keywords
chinazoline derivatives
chinazoline
derivatives
Prior art date
Application number
AT07009390T
Other languages
English (en)
Inventor
Nicola Murdoch Heron
Andrew Austen Mortlock
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE438644T1 publication Critical patent/ATE438644T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07009390T 2002-12-24 2003-12-22 Chinazolinderivate ATE438644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
ATE438644T1 true ATE438644T1 (de) 2009-08-15

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03782672T ATE370958T1 (de) 2002-12-24 2003-12-22 Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
AT07009390T ATE438644T1 (de) 2002-12-24 2003-12-22 Chinazolinderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03782672T ATE370958T1 (de) 2002-12-24 2003-12-22 Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung

Country Status (29)

Country Link
US (4) US7528121B2 (de)
EP (2) EP1847539B1 (de)
JP (3) JP4422102B2 (de)
KR (1) KR101010299B1 (de)
AR (2) AR042668A1 (de)
AT (2) ATE370958T1 (de)
AU (1) AU2003290313B2 (de)
BR (1) BRPI0317717B8 (de)
CA (1) CA2511613C (de)
CL (1) CL2003002731A1 (de)
CY (2) CY1107775T1 (de)
DE (2) DE60315892T2 (de)
DK (2) DK1578755T3 (de)
ES (2) ES2329623T3 (de)
IL (2) IL169112A (de)
IS (2) IS2504B (de)
MX (1) MXPA05006918A (de)
MY (2) MY147761A (de)
NO (2) NO335193B1 (de)
NZ (1) NZ540698A (de)
PL (2) PL223998B1 (de)
PT (2) PT1847539E (de)
RU (3) RU2357971C2 (de)
SA (1) SA04240504B1 (de)
SI (2) SI1578755T1 (de)
TW (2) TWI393710B (de)
UA (1) UA83814C2 (de)
UY (1) UY28149A1 (de)
WO (1) WO2004058781A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
US7528121B2 (en) 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
AU2004247626B8 (en) * 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1802608A1 (de) * 2004-10-12 2007-07-04 AstraZeneca AB Chinazolinderivate zum einsatz gegen krebs
WO2006040520A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
ES2616255T3 (es) 2008-04-30 2017-06-12 National Health Research Institutes Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas
JP2011526912A (ja) * 2008-07-03 2011-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのナフチリジノン
EP2361254A1 (de) * 2008-12-05 2011-08-31 ArQule, Inc. Raf-inhibitoren und anwendungen davon
EP2373326B1 (de) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Kristalline formen von genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
BRPI0923579A2 (pt) 2008-12-22 2020-01-14 Millennium Pharm Inc combinação de inibidores de aurora quinase e anticorpos anti-cd20
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
EP2956138B1 (de) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015019624A2 (pt) * 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
HUE034490T2 (en) * 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
HUE066413T2 (hu) 2017-09-08 2024-08-28 Univ Leland Stanford Junior ENPP1 inhibitorok és alkalmazásuk rák kezelésére
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
EP0584222B1 (de) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (de) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
BR9914326A (pt) * 1998-10-08 2001-06-26 Astrazeneca Ab Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
EP1289952A1 (de) 2000-05-31 2003-03-12 AstraZeneca AB Indolderivate mit gefässschädigender aktivität
WO2002000649A1 (en) * 2000-06-28 2002-01-03 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CA2426440C (en) * 2000-08-18 2011-03-15 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (de) * 2001-06-21 2004-10-20 Ariad Pharma Inc Neue chinazoline und ihre verwendungszwecke
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
CA2508921A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
US7528121B2 (en) * 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer

Also Published As

Publication number Publication date
NO335193B1 (no) 2014-10-20
US20140162984A1 (en) 2014-06-12
TWI336327B (en) 2011-01-21
TWI393710B (zh) 2013-04-21
AU2003290313A1 (en) 2004-07-22
AU2003290313B2 (en) 2007-05-10
SI1847539T1 (sl) 2010-01-29
US9567358B2 (en) 2017-02-14
US20100069412A1 (en) 2010-03-18
PL223998B1 (pl) 2016-11-30
BR0317717A (pt) 2005-11-22
US20150307534A1 (en) 2015-10-29
JP2007326862A (ja) 2007-12-20
HK1111417A1 (en) 2008-08-08
KR20050088333A (ko) 2005-09-05
EP1847539B1 (de) 2009-08-05
PT1578755E (pt) 2007-10-19
IL169112A0 (en) 2009-02-11
IS8714A (is) 2008-02-13
JP4503090B2 (ja) 2010-07-14
CY1107775T1 (el) 2013-06-19
DK1847539T3 (da) 2009-11-09
DK1578755T3 (da) 2007-11-12
PL377680A1 (pl) 2006-02-06
SA04240504B1 (ar) 2008-04-01
NZ540698A (en) 2008-05-30
NO20052855D0 (no) 2005-06-13
ES2329623T3 (es) 2009-11-27
DE60328735D1 (de) 2009-09-17
SA04240504A (ar) 2005-12-03
IL185176A0 (en) 2007-12-03
IS7948A (is) 2005-07-20
US8268841B2 (en) 2012-09-18
NO20052855L (no) 2005-08-03
NO335446B1 (no) 2014-12-15
RU2005123485A (ru) 2006-03-10
EP1578755B1 (de) 2007-08-22
US20060116357A1 (en) 2006-06-01
EP1578755A1 (de) 2005-09-28
ES2290529T3 (es) 2008-02-16
CY1109479T1 (el) 2014-08-13
HK1080481A1 (en) 2006-04-28
DE60315892D1 (de) 2007-10-04
UA83814C2 (ru) 2008-08-26
BRPI0317717B1 (pt) 2017-12-19
TW201102369A (en) 2011-01-16
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
CL2003002731A1 (es) 2005-01-07
WO2004058781A1 (en) 2004-07-15
JP4422102B2 (ja) 2010-02-24
IL169112A (en) 2010-12-30
UY28149A1 (es) 2004-07-30
MXPA05006918A (es) 2005-08-18
ATE370958T1 (de) 2007-09-15
BRPI0317717B8 (pt) 2021-05-25
PL221490B1 (pl) 2016-04-29
KR101010299B1 (ko) 2011-01-25
PT1847539E (pt) 2009-10-06
SI1578755T1 (sl) 2007-12-31
DE60315892T2 (de) 2008-08-14
US7528121B2 (en) 2009-05-05
IL185176A (en) 2011-10-31
IS2504B (is) 2009-04-15
RU2350611C1 (ru) 2009-03-27
JP2006512418A (ja) 2006-04-13
US9018191B2 (en) 2015-04-28
JP4906608B2 (ja) 2012-03-28
JP2009046514A (ja) 2009-03-05
EP1847539A1 (de) 2007-10-24
MY147761A (en) 2013-01-31
CA2511613A1 (en) 2004-07-15
CA2511613C (en) 2012-10-02
MY136174A (en) 2008-08-29
TW200510342A (en) 2005-03-16
RU2357971C2 (ru) 2009-06-10
RU2007121850A (ru) 2008-12-20
IS2884B (is) 2014-06-15
NO20131444L (no) 2005-08-03
PL412704A1 (pl) 2015-10-12

Similar Documents

Publication Publication Date Title
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
ATE420066T1 (de) Amidoacetonitrilderivate
ATE352550T1 (de) Chinazolinderivate
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE354365T1 (de) N-thiazol-2-yl-benzamid-derivate
NO20044253L (no) Polyisobutenaminer
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATA19152002A (de) Hubkupplung
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
ATA16872002A (de) Zwischenstück
ATE395327T1 (de) Amidoacetonitrilderivate
DK1503988T3 (da) Fredericamycin-derivater
ATA15092002A (de) Beckenräumer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1847539

Country of ref document: EP